Education
About Us
Working with TipRanks
Follow Us
Innocan Pharma Corporation (INNPF)
:INNPF
INNPF Stock Chart & Stats
Day’s Range― - ―
52-Week Range$0.09 - $0.24
Previous CloseN/A
Volume45.00K
Average Volume (3M)33.00
Market Cap
$35.30M
Enterprise ValueN/A
Total Cash (Recent Filing)$5.06M
Total Debt (Recent Filing)$1.00K
Price to Earnings (P/E)―
Beta-0.18
Next Earnings
Jun 02, 2025EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)>-0.01
Shares Outstanding290,115,500
10 Day Avg. Volume0
30 Day Avg. Volume33
Financial Highlights & Ratios
PEG Ratio-0.34
Price to Book (P/B)8.05
Price to Sales (P/S)0.00
P/FCF Ratio-16.98
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
---
InnoCan Pharma News
PremiumCompany Announcements
Innocan Pharma Secures First Mexican Patent for Cannabis-Based Pain Relief
PremiumCompany Announcements
Innocan Pharma Closes Private Placement to Bolster Operations
PremiumCompany Announcements
Innocan Pharma Expands IP in Asia and Announces Private PlacementPremiumCompany Announcements
Innocan Pharma’s 2024 Revenue Surges Amid Strategic Growth
PremiumCompany Announcements
Innocan Pharma Announces $1 Million Debenture Offering to Tamar Innovest
PremiumCompany Announcements
Innocan Pharma Secures Indian Patent for Liposomal CBD InjectionPremiumCompany Announcements
Innocan Pharma’s Subsidiary Achieves Safety and Sales Milestones---
Options Prices
Currently, No data available
---
Ownership Overview
INNPF FAQ
What was Innocan Pharma Corporation’s price range in the past 12 months?
Innocan Pharma Corporation lowest stock price was $0.09 and its highest was $0.24 in the past 12 months.
What is Innocan Pharma Corporation’s market cap?
Innocan Pharma Corporation’s market cap is $35.30M.
When is Innocan Pharma Corporation’s upcoming earnings report date?
Innocan Pharma Corporation’s upcoming earnings report date is Jun 02, 2025 which is in 16 days.
How were Innocan Pharma Corporation’s earnings last quarter?
Innocan Pharma Corporation released its earnings results on Mar 31, 2025. The company reported $0 earnings per share for the quarter, the consensus estimate of N/A by $0.
Is Innocan Pharma Corporation overvalued?
According to Wall Street analysts Innocan Pharma Corporation’s price is currently Overvalued.
Does Innocan Pharma Corporation pay dividends?
Innocan Pharma Corporation does not currently pay dividends.
What is Innocan Pharma Corporation’s EPS estimate?
Innocan Pharma Corporation’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Innocan Pharma Corporation have?
Innocan Pharma Corporation has 290,115,500 shares outstanding.
What happened to Innocan Pharma Corporation’s price movement after its last earnings report?
Innocan Pharma Corporation reported an EPS of $0 in its last earnings report, expectations of N/A. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Innocan Pharma Corporation?
Currently, no hedge funds are holding shares in INNPF
---
Company Description
Innocan Pharma Corporation
InnoCan Pharma Corporation, a pharmaceutical company, focuses on the development of various drug delivery platforms combining cannabidiol (CBD) with other pharmaceutical ingredients in the United States, Poland, France, and internationally. The company engages in the research and development of COVID-19 and other condition treatment by using CBD loaded exosomes; and CBD loaded liposomes. Its product includes CBD eye serum, CBD face oil, CBD face cream, CBD facial serum, CBD sleeping mask, CBD recovery lotion, and the Relief & Go spray. The company is also involved in the commercialization and sale of branded CBD integrated pharmaceutical and topical treatment products. InnoCan Pharma Corporation was incorporated in 2018 and is headquartered in Calgary, Canada.
---
Technical Analysis
Mountain Valley MD
―
Medicure
―
Medexus Pharmaceuticals Inc
―
Revive Therapeutics
―
BioNxt Solutions
―
---